A Bayesian approach for incorporating economic factors in sample size design for clinical trials of individual drugs and portfolios of drugs

Statistics in Medicine

Volumn 26, Issue 27, 2007, Pages 4976-4988

  Patel, Nitin R ^a,b   Ankolekar, Suresh ^c  

^a Cytel Incorporated   (United States)

^b MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^c MAASTRICHT SCHOOL OF MANAGEMENT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

BAYES THEOREM; BUDGET; CONFERENCE PAPER; CONTROLLED STUDY; DECISION MAKING; DECISION THEORY; DRUG INDUSTRY; DRUG RESEARCH; ECONOMICS; FINANCIAL MANAGEMENT; MATHEMATICAL COMPUTING; PROFIT; RISK ASSESSMENT; SAMPLE SIZE;

BAYES THEOREM; CLINICAL TRIALS AS TOPIC; DECISION SUPPORT TECHNIQUES; DRUG COSTS; HUMANS; MODELS, ECONOMIC; RESEARCH DESIGN; SAMPLE SIZE;

EID: 35949003229     PISSN: 02776715     EISSN: 10970258     Source Type: Journal    
DOI: 10.1002/sim.2955     Document Type: Conference Paper

References (21)

1. Spiegelhalter DJ, Abrams KR, Myles JP. Bayesian Approaches to Clinical Trials and Health-Care Evaluation. Wiley: London, 2004.
2. O'Hagan A, Stevens JW, Campbell MJ. Assurance in clinical trial design. Pharmaceutical Statistics 2005; 4:187-201. DOI: 10.1002/ pst.175
3. Lee SJ, Zelen M. Clinical trials and sample size considerations: another perspective. Statistical Science 2000; 15:95-110.
4. Stallard N, Whitehead J, Cleall S. Decision-making in a phase II clinical trial: a new approach combining Bayesian and frequentist concepts. Pharmaceutical Statistics 2005; 4:119-128. DOI: 10.1002/pst.164
5. Halpern J, Brown BWM, Hornberger J. The sample size for a clinical trial: a Bayesian-decision theoretic approach. Statistics in Medicine 2001; 20:841-858.
6. Willan AR, Pinto EM. The value of information and optimal clinical trial design. Statistics in Medicine 2005; 24:1791-1806. DOI: 10.1002/sim.2069
7. Berry DA. Decision analysis and Bayesian methods in clinical trials. In Recent Advances in Clinical Trial Design and Analysis, Thall PF (ed.). Kluwer Academic Publishers: Boston, 1995.
8. Berry DA. Bayesian statistics and the efficiency and ethics of clinical trials. Statistical Science 2004; 19:175-187.
9. Gittin J, Pezeshk H. How large should a clinical trial be? The Statistician 2000; 49:1-14.
10. Julious SA, Swank DJ. Moving statistics beyond the individual clinical trial: applying decision science to optimize a clinical development plan. Pharmaceutical Statistics 2005; 4:37-46. DOI: 10.1002/pst.149
11. Burman C-F, Hamren B, Olsson P. Modelling and simulation to improve decision-making in clinical development. Pharmaceutical Statistics 2005; 4:47-58. DOI: 10.1002/pst.153
12. Stallard N. Decision-theoretic designs for phase II clinical trials allowing for competing studies. Biometrics 2003; 59:402-409.
13. Hornberger JC, Brown BWM, Halpern J. Designing a cost-effective clinical trial. Statistics in Medicine 1995; 14:2249-2259.
14. Willan AR, Lin DY. Incremental net benefit in randomized clinical trials. Statistics in Medicine 2001; 20:1563-1574. DOI: 10.1002/sim.789
15. Pinto EM, Willan AR, O'Brien BJ. Cost-effectiveness analysis for multinational clinical trials. Statistics in Medicine 2005; 24:1965-1982. DOI: 10.1002/sim.2078
16. Hornberger J, Eghtesady P. The cost-benefit of a randomized trial to a health care organization. Controlled Clinical Trials 1998; 19:198-211.
17. Chow S, Shao J, Wang H. Sample Size Calculations in Clinical Research. Marcel Dekker: New York, 2003.
18. Markowitz HM. Portfolio Selection: Efficient Diversification of Investments. Blackwell: Oxford, 1991.
19. Ibakari T, Katoh H. Resource Allocation Problems. MIT Press: Cambridge, MA, 1988.
20. Parzen E. Modern Probability Theory and its Applications. Wiley: New York, 1992.
21. Keeney RL, Raiffa H. Decisions with Multiple Objectives: Preferences and Value Tradeoffs. Wiley: New York, 1976.